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OBJECTIVES We sought to determine whether coronary vascular nitric oxide (NO) release in vivo
modulates platelet activation.
BACKGROUND Nitric oxide modulates vasodilator tone and platelet activity via the cyclic guanosine
monophosphate (cGMP) pathway, but whether coronary endothelial dysfunction influences
platelet activation in humans is unknown.
METHODS In 26 patients, we measured coronary blood flow, epicardial diameter and coronary sinus
platelet cGMP content during intracoronary infusions of acetylcholine (ACH), L-NG
monomethyl arginine (L-NMMA) and sodium nitroprusside.
RESULTS Acetylcholine increased platelet cGMP content (p 5 0.013), but its magnitude was lower in
patients with endothelial dysfunction; thus, patients with epicardial constriction with ACH
had a 7 6 6%, p 5 ns change compared with a 32 6 13%, p 5 0.05 increase in platelet cGMP
in those with epicardial dilation. Similarly, patients with atherosclerosis or its risk factors had
a smaller increase (9 6 6%) compared with those having normal coronary arteries without risk
factors (51 6 22%, p 5 0.019). L-NG monomethyl arginine decreased platelet cGMP
content to a greater extent in patients with epicardial dilation with ACH (215 6 7%, p 5
0.06) compared to those with constriction (15 6 6% change, p 5 0.5). Sodium nitroprusside
produced a similar increase in platelet cGMP content in patients with and without
endothelial dysfunction (p 5 0.56). The effects of sodium nitroprusside, but not ACH or
L-NMMA, were reproduced in vitro.
CONCLUSIONS Platelet cGMP levels can be modulated by basal and stimulated release of NO. The platelet
inhibitory effect of NO is reduced in patients with endothelial dysfunction, which may explain
their increased risk from thrombotic events and the improved survival associated with
strategies designed to improve vascular function. (J Am Coll Cardiol 2001;37:510–6) ©
2001 by the American College of Cardiology
The vascular endothelium modulates smooth muscle tone
by the abluminal release of endothelium-derived relaxing
factors (1–5), including nitric oxide (NO) or an adduct of
NO. By simultaneously diffusing into the lumen (6,7), NO
potently inhibits platelet adhesion, and to a lesser extent
aggregation, by increasing cytosolic levels of cyclic
guanosine monophosphate (cGMP)(8–12). In whole blood,
where the half-life of NO is attenuated by hemoglobin and
other oxidants, the platelet inhibitory effects are less easily
demonstrated and may be insignificant (13–15). Nonethe-
less, exogenous NO can markedly inhibit platelet adhesion,
and inhibition of NO synthesis promotes platelet aggrega-
tion and cyclic flow variations (16,17).
In humans, acetylcholine (ACH) stimulates NO release
from normal endothelium, but bioavailability of both basal
and stimulated NO is reduced in patients with atheroscle-
rosis or its risk factors (18–20). Although much is known
about NO bioactivity in vascular smooth muscle, studies
examining the in vivo effects of endothelium-derived NO
on platelet function in humans are sparse, and whether any
inhibitory action of NO on platelets is depressed in patients
with endothelial dysfunction is unknown. Therefore, in the
present study, we have investigated whether basal or phar-
macologic stimulation of endothelial NO activity causes
inhibition of platelet activation by increasing platelet cGMP
levels, and whether atherosclerosis and its risk factors,
when accompanied by abnormal dilator responses to
endothelium-dependent agents, are also associated with a
defect in the platelet inhibitory effects of the vessel wall. For
this purpose, we studied the effects of inhibition and
stimulation of coronary vascular NO activity in the human
coronary circulation.
METHODS
Patients. Twenty-six patients, 14 male, average age 50 6 2
years (range 28 to 73 years), undergoing elective cardiac
catheterization for evaluation of chest pain were recruited in
the study. Those with valvular heart disease or acute
coronary syndromes were excluded. Twenty patients had
angiographically smooth-appearing coronary arteries and six
had minimal luminal irregularities (,10% stenosis). Pa-
tients with obstructive disease in the left coronary circula-
tion were excluded because of the potential for platelet
activation with increased shear (21). Eleven patients were
hypertensive (arterial pressure .140/90), five were diabetic,
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mean total cholesterol was 225 6 9 mg/dl and two had
mild impairment of left ventricular function. Risk factors
for atherosclerosis, defined as age .60 years, cholesterol
.240 mg/dl, hypertension, diabetes and tobacco smoking
within the previous two years, were present in 19 patients.
Aspirin and nonsteroidal anti-inflammatory agents were
withdrawn for at least seven days and cardiac medications
for 48 h prior to the study. The study was approved by the
Institutional Review Board of the National Heart, Lung,
and Blood Institute and all patients gave written informed
consent.
Protocol. A 7-F multipurpose A2 catheter (Cordis Inc.,
Miami, Florida) was placed in the coronary sinus for blood
sampling. Patients received 10,000 IU of intravenous hep-
arin and all drugs were administered into the left main
coronary artery. A 0.018 inch Doppler flow wire was placed
in the proximal left anterior descending coronary artery to
measure flow velocity (Fig. 1).
Patients with coronary atherosclerosis received 2-min
infusions of ACH at 3 mg/min and 30 mg/min (1027 and
1026 mol/l intracoronary concentration, respectively). Pa-
tients with normal coronary arteries received 30 mg/min
ACH and 12 patients who did not vasoconstrict at this dose
received 100 mg/min ACH (3.3 3 1026 mol/l intracoronary
concentration). After a 10-min recovery period, intracoro-
nary sodium nitroprusside (40 mg/min) was infused for
3 min (n 5 22). After recovery sampling, 64 mmol/min
(4 3 1024 mol/l) L-NG monomethyl arginine (L-NMMA,
Clinalfa, Switzerland) was infused for 5 min (n 5 23). In 11
patients, the maximum dose of ACH (mean dose 2.5 3
1026 mol/l) was reinfused. Blood samples from the coronary
sinus were obtained after each infusion (Fig. 1).
Estimation of coronary blood flow and diameter. Coro-
nary angiograms were recorded using a cine angiographic
system (Toshiba, Inc., Japan) and quantitative angiography
was performed with ARTEK software (Quantim 2001,
Statview, Image Comm Systems, Inc., Mountain View,
California). Coronary blood flow was estimated from the
flow velocity and diameter measurements using the formula
(p 3 average peak velocity 3 0.125 3 diameter2)(18,22).
Coronary vascular resistance was calculated as mean arterial
pressure 4 coronary blood flow. For calculating flow,
coronary artery diameter was measured in a 0.5 cm segment
of vessel beginning 0.25 cm beyond the tip of the flow wire,
and a segment of vessel distal to the flow wire was analyzed
in all subjects for delineating diameter changes with each
infusion. Only distal diameter changes are reported as
percent change compared with the baseline before drug
infusion.
Measurement of platelet and plasma cGMP. Nine mil-
liliters of blood was drawn into syringes containing 1 ml
sodium citrate (14.7 mmol/l) and zaprinast (1025 mol/l).
Within 1 min of sampling, the blood was centrifuged at
140 g for 10 min. Two 1-ml aliquots of the resultant
platelet-rich plasma were centrifuged at 2,500 g for 2 min to
obtain a platelet pellet. After careful removal of all the
plasma supernatant, ice-cold 6% trichloroacetic acid was
added to extract the cGMP. After neutralization by solvent
partition with a mixture of Freon and tri-n-octylamine,
cGMP was measured by radioimmunoassay (RPA 525,
Amersham International, United Kingdom). Platelet counts
(Elzone particle counter, Particle Data Inc., Elmhurst,
Illinois) were performed on each sample of platelet rich
plasma.
Plasma cGMP levels were simultaneously measured in 11
patients. Two 100-ml aliquots of platelet-poor plasma
samples were added to ice-cold 6% trichloroacetic acid;
cGMP was then extracted and assayed as described in the
preceding text.
Reproducibility of the coronary sinus cGMP sampling
was assessed by repeat measurements in seven patients with
minimal coronary atherosclerosis. Between the two mea-
surements, the variability was 7.5 6 5.5%, r 5 0.97 (p 5
0.0003), and the means were similar (0.94 6 0.13 and
0.99 6 0.13 pmol/109 plts., p 5 0.8).
In vitro effects of ACH, sodium nitroprusside and
L-NMMA. Blood from 10 healthy volunteers (five male)
and three patients (one male) with normal coronary arteries
was drawn into syringes containing Hirudin (final concen-
tration 20 mg/ml). Within 2 min of sampling, ACH (0.01,
0.1 and 1.0 mg/ml, n 5 5), sodium nitroprusside (0.125 and
0.25 mg/ml, n 5 7), or L-NMMA (2 3 1024 mol/L and
4 3 1024 mol/L, n 5 7), and a control volume of saline
were added to 9-ml aliquots of blood. Following 5 min of
incubation at 37°C, citrate and zaprinast (concentrations as
in the preceding text) were added and the samples were
processed for measurement of cGMP as in the in vivo study.
In vitro concentrations were calculated to mimic intra-
coronary levels achieved during infusion of ACH at 3 to
100 mg/min, sodium nitroprusside at 40 mg/min, and
L-NMMA at 32 and 64 mmol/min.
Statistical analysis. Data are expressed as a mean 6 SEM.
Difference between means were compared by the Student t
Abbreviations and Acronyms
ACH 5 acetylcholine
ANOVA 5 analysis of variance
cGMP 5 cyclic guanosine monophosphate
NO 5 nitric oxide
L-NMMA 5 L-NG monomethyl arginine
Figure 1. Protocol design. L-NMMA 5 L-NG monomethyl arginine.
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test or the one-way analysis of variance (ANOVA) (23) for
repeated measures using SAS software (Version 6.12; SAS
Institute, Cary, North Carolina). If the F value was signif-
icant, a Bonferroni multiple-comparison test was per-
formed. A p value of #0.05 was considered statistically
significant. To identify the most parsimonious multivariate
model for predicting change in platelet cGMP level with
ACH, we used the SAS Stepwise Procedure (stepwise
technique) on the regressor’s age, gender, the presence of
hypertension, diabetes, cigarette use or cholesterol level; or
on the diameter and flow changes with ACH (30 mg/min)
or the diameter or flow changes with L-NMMA (24). The
significance level for covariate entry and staying in the
model was 0.15.
RESULTS
Effect of ACH on the coronary vasculature and platelet
cGMP levels. There was progressive vasodilation with
ACH; coronary vascular resistance was 41 6 8% lower (p ,
0.001) with 1026 mol/l ACH. Coronary diameter changes
were heterogeneous (mean 1 6 3% change). Acetylcholine
evoked an increase in platelet cGMP content (p 5 0.013,
ANOVA) with a 21 6 8% increase with 1026 mol/l ACH
(Fig. 2). Plasma cGMP levels during ACH were slightly
higher compared to baseline (3.9 to 4.6 nmol/l, p 5 0.04).
However, there was no correlation between changes in
platelet and plasma cGMP levels (r 5 0.3, p 5 0.1). Platelet
cGMP levels were adjusted for plasma cGMP concentra-
tions assuming contamination of the platelet pellet samples
with 10 mL of plasma. The increase in platelet cGMP with
intracoronary ACH was unaffected by this correction (un-
corrected 22 6 11%, corrected 23 6 10% increase).
To investigate the relationship between the vascular and
platelet responses, we divided patients into those with and
without endothelial dysfunction based on 1) epicardial
coronary artery response to ACH and 2) presence or
absence of atherosclerosis or its risk factors.
Eleven subjects had constriction in the distal epicardial
diameter (mean 211 6 3%) in response to 1026 mol/l
ACH (endothelial dysfunction) and 15 subjects vasodilated
(mean 10 6 2%) (normal endothelial function, Fig. 3).
Patients who constricted with ACH had no significant
change in coronary sinus platelet cGMP content (7 6 6%,
p 5 ns), whereas those with epicardial vasodilation with
ACH had a significant increase (32 6 13%, p 5 0.05 by
ANOVA, Fig. 3). Microvascular vasodilation in response to
ACH was also reduced in patients with epicardial constric-
tion: coronary blood flow in response to 1026 mol/l ACH
increased by 166 6 25% in those with epicardial dilation
compared with a 52 6 20% (p 5 0.04) increase in those
with epicardial constriction.
Impact of atherosclerosis and its risk factors on platelet
function. For this analysis, patients with coronary athero-
sclerosis and those with risk factors for atherosclerosis but
normal coronary arteries were combined (atherosclerosis
group, n 5 19) and compared to those with normal
coronary arteries without risk factors for atherosclerosis
(normal group, n 5 7). Compared to the atherosclerosis
group, the normal group had greater microvascular (p 5
0.017) and epicardial dilation (p 5 0.047) with 1026 mol/l
ACH (Fig. 4). The increase in platelet cGMP level in the
normal group (51 6 22%) was significantly greater than the
change in the atherosclerosis group of patients (9 6 6%, p 5
0.019 between groups) (Fig. 4).
Multivariate regression analysis investigated whether the
change in platelet cGMP content with ACH was related to
the presence of risk factors (age, presence of hypertension,
diabetes, smoking history, atherosclerosis, cholesterol or
HDL levels), or the diameter or coronary vascular resistance
responses to 1026 mol/l ACH. The change in cGMP
content with ACH was independently related to the change
in epicardial diameter with ACH (a measure of endothelial
dysfunction, r2 5 0.31, p 5 0.009).
Effect of sodium nitroprusside. Intracoronary sodium ni-
troprusside evoked significant epicardial and microvascular
dilation; coronary vascular resistance decreased by 58 6 5%
and epicardial arteries dilated by 10 6 6% (both p , 0.001).
Figure 2. Changes in coronary sinus platelet cGMP content, coronary
blood flow and epicardial diameter during intracoronary infusion of
acetylcholine (n 5 26). All tests use one-way analysis of variance. cGMP 5
cyclic guanosine monophosphate.
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Platelet cGMP content in coronary sinus blood increased by
247 6 38% from 0.78 6 1.12 to 2.4 6 0.4 pmol/109
platelets (p , 0.0001), with similar increases in normal
controls and the group with atherosclerosis, or in patients
with epicardial constriction (endothelial dysfunction) with
ACH (214 6 68%) and those with epicardial dilation
(264 6 47%, p 5 0.56) (Fig. 4). There was no change in
plasma cGMP with sodium nitroprusside (4.4 6 1.3 nmol/l
with and 4.8 6 0.8 nmol/l before, p 5 0.8).
Effect of L-NMMA. Intracoronary L-NMMA produced
coronary epicardial and microvascular constriction; coronary
vascular resistance was 12 6 6% (p 5 0.016) higher and
epicardial diameter 26 6 2% narrower (p 5 0.018).
Compared with baseline, platelet cGMP content was lower
after L-NMMA; 0.92 6 1.5 to 0.75 6 1 pmol/109 platelets,
p 5 0.05. Patients with constriction of epicardial coronary
arteries with ACH (endothelial dysfunction) had no signif-
icant change in cGMP with L-NMMA (5 6 6% change
compared with baseline, p 5 0.5), whereas those who
dilated with ACH (normal endothelium) had a trend
toward reduction in cGMP with L-NMMA (215 6 7%
reduction compared with baseline, p 5 0.06).
Patients in the normal group tended to have greater
epicardial and microvascular constriction with L-NMMA
compared with those in the atherosclerosis group; coronary
blood flow was 214 6 5% lower compared with 17 6 6%
change respectively, p 5 0.07, and coronary diameter
constricted by 213 6 3% versus 24 6 2% respectively, p 5
0.04. Similarly, coronary sinus platelet cGMP content with
L-NMMA was 22 6 10% lower compared with baseline in
the normal group, but no change (21 6 6%) was seen in the
atherosclerosis group (p 5 0.08 between groups).
There was a negative correlation between the magnitude
of change in platelet cGMP level with ACH and
L-NMMA (R 5 20.66, p 5 0.002), indicating that
patients with greater increase in cGMP with ACH had
greater decrease with L-NMMA and vice versa. Finally,
there was no change in plasma cGMP with L-NMMA
(4.8 6 0.8 before vs. 4.9 60.7 nmol/l after, p 5 0.8).
Effect of L-NMMA on the response to ACH. As ex-
pected, L-NMMA inhibited the vascular response to ACH;
coronary vascular resistance was 1.18 6 0.2 mm Hg.min.ml21
with ACH before and 2.3 6 0.6 mm Hg.min.ml21, p 5 0.05,
Figure 3. Acetylcholine-mediated changes in coronary sinus platelet
cGMP content and coronary blood flow in patients with (n 5 11) (dashed
lines) and those without (n 5 15) (solid lines) epicardial coronary
constriction with 1026mol/l acetylcholine. Baseline coronary blood flow
(40.7 6 9 vs. 43.6 6 8 ml/min, p 5 0.8) and platelet cGMP content
(0.72 6 0.1 vs. 0.83 6 0.2 pmol/109 platelets, p 5 0.6) were not
significantly different between patients with epicardial constriction com-
pared to those with dilation in response to acetylcholine. Differences
between groups by analysis of variance. cGMP 5 cyclic guanosine
monophosphate.
Figure 4. Changes in coronary sinus platelet cGMP content, coronary blood flow and epicardial diameter during intracoronary acetylcholine (1026 mol/l)
and sodium nitroprusside (40 mg/min) infusions in patients with (n 5 19) (shaded bars) and those without (n 5 7) (open bars) atherosclerosis or its risk
factors. Baseline coronary blood flow (30.7 6 5 vs. 43.6 6 7 ml/min), coronary diameter (2.3 6 0.6 vs 2.2 6 0.6 mm) and platelet cGMP content (0.76 6
0.2 vs. 0.79 6 0.1 pmol/109 platelets) were not significantly different between patients with and those without atherosclerosis or its risk factors, p . 0.2.
Open bars 5 normal; solid bars 5 atherosclerosis or risk factors. *p , 0.05, **p , 0.02. cGMP 5 cyclic guanosine monophosphate.
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after L-NMMA. The 12 6 8% increase in platelet cGMP
with ACH in the control study tended to be lower after
L-NMMA (28 6 8%, p 5 0.08) in the group as a whole.
However, the seven patients in the normal group who had an
increase in cGMP with ACH in the control study had no
change after L-NMMA (26 6 8% increase vs. 26 6 12%
change, p 5 0.05 respectively), indicating that the increase in
platelet cGMP content with ACH was due to stimulation of
NO by ACH.
In vitro effects of ACH, L-NMMA and sodium nitro-
prusside. To determine whether the observed effects on
cGMP levels were due to a direct intraluminal action of
these vasoactive agents on platelets, or indirectly via their
action on the vascular endothelium, we performed in vitro
experiments where whole blood was incubated with ACH,
L-NMMA, and sodium nitroprusside in concentrations
achieved in vivo during intracoronary delivery. There was no
effect of ACH or L-NMMA on platelet cGMP content at
concentrations achieved in vivo (Fig. 5). Incubation of
whole blood with sodium nitroprusside produced a 202 6
53% (p 5 0.013) increase in platelet cGMP level, a change
that is comparable to the 254 6 77% increase observed
during intracoronary administration (Fig. 5).
DISCUSSION
Our study demonstrates that: 1) stimulation of endothelium-
derived NO release by ACH into the vascular lumen
increases platelet cGMP content, 2) luminal NO availability
is reduced in patients with coronary vascular endothelial
dysfunction (those with risk factors for atherosclerosis and
angiographic atherosclerosis, or those with epicardial con-
striction with intracoronary ACH), and 3) inhibition of NO
synthase by L-NMMA decreases platelet cGMP content, a
change that was not observed in patients with endothelial
dysfunction. Thus, the human coronary endothelium mod-
ulates platelet cGMP levels and hence platelet passivation in
vivo, both at rest and during pharmacologic stimulation.
Because NO appears to be the only agent capable of
enhancing platelet cGMP activity (6) and the effects of
ACH were inhibited by L-NMMA, it is likely that the
observed action of ACH was due to stimulation of NO
activity. Finally, the actions of ACH and L-NMMA in vivo
were primarily via their effect on the endothelium and could
not be explained by a direct action of these agents on
platelets in in vitro studies.
The significant correlation between vasomotor and plate-
let cGMP responses highlights the close relationship be-
tween the effects of the vascular endothelium on smooth
muscle tone and platelet function. Thus, endothelial dys-
function not only impairs vasodilation by the deficient
abluminal activity of NO, but also depresses the antithrom-
botic properties of the vascular endothelium.
Effect of ACH on platelets. Acetylcholine, by promoting
NO release, causes smooth muscle relaxation by increasing
soluble cGMP levels (1,6–15,25) a mechanism that is also
responsible for inhibition of platelet aggregation and adhe-
sion (8–12,26). Intravenous carbachol inhibits platelet ag-
gregation and increases platelet cGMP content (14) and
adducts of NO inhibit platelet aggregation in vivo (27,28).
Despite these apparently consistent results in experimental
models, it is not known whether endogenous NO has a
significant in vivo effect on platelets in humans, especially
because the half-life of NO is dramatically shortened in
whole blood by hemoglobin and other oxidants (29–32).
We previously demonstrated inhibition of ex vivo platelet
aggregation with ACH infusion (33), and together with the
current findings provide convincing evidence that
endothelium-derived NO can inhibit platelet activation in
vivo.
Ex vivo measurement of cGMP may underestimate the
effect on guanylate cyclase, either because of decay of cGMP
(34,35) or dilution from the nonocclusive sampling tech-
nique used. Moreover, the platelet-inhibitory effect of NO
may not be entirely mediated by cGMP because NO may
Figure 5. Percent change in platelet cGMP content during in vitro incubation with acetylcholine, sodium nitroprusside and L-NMMA is shown in open
circles. For comparison, the effect of these agonists at estimated intracoronary concentrations achieved during in vivo administration in the normal subjects
are shown in closed circles. *p # 0.05, **p , 0.001 compared to baseline. cGMP 5 cyclic guanosine monophosphate; L-NMMA 5 L-NG monomethyl
arginine.
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form an adduct with hemoglobin (S-nitrosohemoglobin)
that releases NO at low oxygen tensions and therefore have
platelet inhibitory effects independent of platelet cGMP
(36,37).
Endothelial dysfunction and platelet activation. Coro-
nary endothelial dysfunction is characterized by epicardial
constriction and reduced microvascular vasodilation in re-
sponse to ACH (18–20,38–40). In this study, patients with
endothelial dysfunction had an insignificant effect of ACH
and L-NMMA on platelet cGMP levels compared with
those having normal endothelial function in whom an
increase in platelet cGMP level was elicited with ACH and
a reduction observed during blockade of NO synthesis.
However, platelets from both groups of patients were
capable of increasing cGMP levels in response to the NO
donor, sodium nitroprusside, indicating that the differences
observed with ACH and L-NMMA were not due to an
intrinsic abnormality of platelet function.
Comparison of platelet responses with ACH and sodium
nitroprusside. Compared to ACH, sodium nitroprusside
produced greater increases in platelet cGMP level for
similar increases in coronary blood flow. This may be due to
continued action of sodium nitroprusside during the extrac-
tion process because sodium nitroprusside, unlike ACH,
directly increased platelet cGMP levels in vitro (41–47).
Alternatively, sodium nitroprusside is capable of acting on
all platelets in the lumen, whereas NO released from the
endothelium in response to ACH is likely to be available
only to a minority of platelets adjacent to the vessel wall
before being metabolized rapidly in blood. Finally, unlike
sodium nitroprusside, ACH causes vasodilation by release
of other NO-independent dilators (4).
Limitations. Because the effects of NO on platelets are
transient and likely to involve platelets close to the vessel
wall, we may have underestimated of the action of ACH
and L-NMMA on platelets (34,35). Cyclic guanosine
monophosphate may also be stimulated by heme oxygenase-
dependent carbon monoxide production, a pathway that can
also be stimulated with ACH and that requires further study
(48,49).
Conclusions. Basal and stimulated release of endogenous
NO from the human coronary endothelium modulates
platelet activity by a cGMP-mediated mechanism. This
platelet-inhibitory effect is lacking in patients with risk
factors for atherosclerosis or those with established athero-
sclerosis who have abnormal endothelial function, which
may explain the increased risk of thrombosis in these
patients (50,51). Because adhesion of platelets to the vessel
wall with subsequent release of growth factors has been
hypothesized as an important mechanism underlying
progression of atherosclerosis (52), our observations re-
garding the potential role of endothelium-platelet inter-
actions in this phenomenon are important and require
further study.
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